Alembic Pharmaceuticals has achieved a significant regulatory milestone by clearing an unannounced USFDA onsite bioequivalence inspection at its Vadodara facility with zero observations. The inspection was conducted from August 31, 2026, to September 10, 2026, providing a clean regulatory pathway for future generic filings. This represents a substantial upgrade from the previous inspection conducted between March 3-7, 2025, which also concluded successfully with an Establishment Inspection Report (EIR). The zero-observation outcome for the Vadodara bioequivalence facility is particularly significant as it removes regulatory overhang and ensures uninterrupted execution of bioequivalence studies, which are mandatory for US generic drug approvals. The facility plays a crucial role in ensuring the bioavailability and bioequivalence of pharmaceutical products, measures essential for maintaining the efficacy and safety of medicines under development.
The drugmaker reported strong financial results for the first quarter, with net profit growing by 11.7% to ₹172 crore from ₹154 crore in the previous year. As reported by CNBC TV18, revenue increased 26% to ₹2,150 crore from ₹1,710 crore in the previous fiscal year. Earnings before interest, taxes, depreciation and amortisation (EBITDA) increased 18.6% to ₹333 crore from ₹280.5 crore in the first quarter last year, though margins contracted to 15.5% from 16.4% in the year-ago period. The company's post R&D EBITDA increased 21% from the previous year, supported by operating leverage expansion and planned strategic expansion in the US branded business. The company has also demonstrated strong financial management by redeeming commercial papers worth ₹150 crore on September 11, 2026, utilizing internal accruals to manage its short-term debt profile.
Alembic Pharmaceuticals demonstrated robust growth across multiple business segments. According to the company's statement, US formulation business growth was up 49% from the previous fiscal year, driven by key product launches and volumes. Excluding US formulations, the company achieved 17% growth, with continued focus on expanding offerings and strengthening market reach. For the India business, Gynaecology, Gastrology and Ophthalmology all showed robust growth, while the performance of the animal healthcare business was described as 'encouraging'. The company's longstanding commitment to quality and regulatory compliance is reflected in the outcome of this recent inspection, with its ability to meet international regulatory standards critical in maintaining its competitive edge in the global pharmaceutical market.
In addition to regulatory success, Alembic Pharmaceuticals has expanded its global footprint by incorporating its wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in Dubai on August 24, 2026, to spearhead international expansion. The successful clearance provides a significant boost to Alembic's US generics pipeline, where the company plans to continuously launch new products. Stable operations at this testing facility will accelerate product approvals, enhancing revenue predictability from the US market. Shares of Alembic Pharmaceuticals ended at ₹823.15, down by ₹0.70, or 0.085%, on the BSE following the announcement. The stock movement reflects market reaction to the mixed financial results and regulatory developments, with investors processing both the positive USFDA inspection closure and the margin contraction in EBITDA despite strong revenue growth. However, this development is expected to bolster confidence in Alembic's manufacturing and operational processes, potentially facilitating smoother market access for its products in the United States.
